Primary Immunodeficiency: cell-therapy evidence and registered trials
A source-first research page for the exact condition. It does not recommend a cell product, clinic or private treatment.
Registry snapshot
ClinicalTrials.gov returned 92 registered studies for the stored condition/intervention query, including 13 recruiting records, retrieved 2026-08-05T06:02:03+00:00. A registry count does not establish efficacy, approval, relevance or eligibility; inspect each study's design, product, status and inclusion criteria.
Research activity over time
Registration of new studies slowed: 10 newly registered studies in 2021–2025 against 24 in 2016–2020. The first study in this registry query was posted in 1999; the registry now holds 92 in total, of which 13 are recruiting. Counting is by first-posted date, so the series reflects when research was registered — not enrolment, completion or results.
Source: ClinicalTrials.gov API v2, retrieved 2026-08-05. A registration count is not evidence of efficacy, approval or eligibility. Open the exact query ↗
What the trial registry actually shows
Our own count of every study registered on ClinicalTrials.gov for primary immunodeficiency with a stem-cell intervention, retrieved 2026-09-05. A registration is a declaration of intent, not a result — which is why the status column matters more than the total.
| Status in the registry | Studies | Share |
|---|---|---|
| Completed | 35 | 38% |
| Active, closed to entry | 14 | 15% |
| Terminated early | 12 | 13% |
| Recruiting now | 12 | 13% |
| Status not updated by sponsor | 9 | 10% |
| Withdrawn before enrolling | 4 | 4% |
| Enrolling by invitation only | 3 | 3% |
| Not yet recruiting | 2 | 2% |
| Expanded access | 1 | 1% |
| Suspended | 1 | 1% |
| All registered studies | 93 | 100% |
Reading it: 17 stopped before finishing — terminated, withdrawn or suspended, 18% of the total; 21 carry no assigned trial phase, meaning they sit outside the phased development path that leads to an approved medicine; 33 reached Phase 2 or later, against 39 still at Phase 1 or earlier; 9 have had no status update from the sponsor and may be dormant.
Counts are our own extraction from the ClinicalTrials.gov API, retrieved 2026-09-05. The query behind them is published with the dataset so anyone can repeat the count. Nothing here is evidence of benefit or a treatment recommendation.
What to verify before interpreting a study or offer
- The exact product, cell source, processing, dose and delivery route.
- The indication, study phase, comparator, endpoints, status and eligibility criteria.
- Whether the proposed use is authorised, part of a registered trial or otherwise investigational.
- Provider and manufacturing authorisations, release testing, traceability and adverse-event reporting.
- How the proposal compares with current standard care, reviewed by an independent physician.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Registry data is a discovery aid, not evidence that a treatment works or is suitable for an individual patient.